Escitalopram
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2002
- First approval year
- 2002
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Escitalopram
- Molecular weight
- 324.4
- Structure (SMILES)
- CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
- cipralex
- Cipralex
- (S)-(+)-CITALOPRAM
- (S)-CITALOPRAM
- cipralex
- Cipralex
- CIPRALEX
- Cipralex®
- escitalopram
- Escitalopram
- ESCITALOPRAM
- Escitalopram [EP MONOGRAPH]
- Escitalopram [INN]
- ESCITALOPRAM [MI]
- Escitalopram [VANDF]
- Escitalopram [WHO-DD]
- escitalopram ep monograph
- escitalopram inn
- escitalopram mi
- escitalopram oxalate
- ESCITALOPRAM OXALATE
- escitalopram vandf
- escitalopram who dd
- esertia
- Esertia
- ESERTIA
- esitol
And 12 more, listed on the interactive page.
- ATC classification codes
- N06AB10
Sources for recorded values
- CAS registry numbers
- 128196-01-0
- ChEMBL ID
- CHEMBL1508
- InChIKey
- WSEQXVZVJXJVFP-FQEVSTJZSA-N
- PubChem compound IDs
- 146570
- FDA ingredient codes (UNII)
- 4O4S742ANY
- 321988
- 353108
- Applicant
- ABBVIE
- Approval date
- 14 Aug 2002
- Application number
- NDA021323
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- escitalopram
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- SERT
- Gene symbol
- SLC6A4
- Protein identifier
- P31645
- Median affinity
- 9
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- SERT
- Gene symbol
- SLC6A4
- Protein identifier
- P31645
- Median affinity
- 8.68
- Affinity units
- pKd
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Serotonin transporter inhibitor
- Action type
- Inhibitor
- Target
- Sodium-dependent serotonin transporter
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- SLC6A4
- Protein identifier
- P31645
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Stroke
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- Stress Disorders, Post-Traumatic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001358
- Subject identifier
- D013313
- Condition
- Cocaine-Related Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002610
- Subject identifier
- D019970
- Condition
- Hepatitis C
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003761
- Subject identifier
- D003865
- Condition
- Renal Insufficiency, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003884
- Subject identifier
- D051436
- Condition
- Substance-Related Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003890
- Subject identifier
- D019966
- Condition
- Obsessive-Compulsive Disorder
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004242
- Subject identifier
- D009771
- Condition
- Panic Disorder
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004262
- Subject identifier
- D016584
- Condition
- Anxiety
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005230
- Subject identifier
- D001007
- Condition
- Fibromyalgia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005687
- Subject identifier
- D005356
- Condition
- Bipolar Disorder
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009963
- Subject identifier
- D001714
- Condition
- Digestive System Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0010282
- Subject identifier
- D004066
- Condition
- Premature Ejaculation
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0803321
- Subject identifier
- D061686
- Condition
- Burning Mouth Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000850
- Subject identifier
- D002054
- Condition
- Anxiety Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001892
- Subject identifier
- D001008
- Condition
- Phobic Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001908
- Subject identifier
- D010698
- Condition
- Phobia, Social
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001917
- Subject identifier
- D000072861
- Condition
- Dementia
- Highest recorded phase
- 3
- Condition identifier
- HP:0000726
- Subject identifier
- D003704
- Condition
- Aphasia
- Highest recorded phase
- 2
- Condition identifier
- HP:0002381
- Subject identifier
- D001037
- Condition
- Borderline Personality Disorder
- Highest recorded phase
- 2
- Condition identifier
- HP:0012076
- Subject identifier
- D001883
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Depressive Disorder
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003866
And 7 more, listed on the interactive page.
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000712
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001074
- Condition identifier
- EFO_0001358
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002610
- Condition identifier
- EFO_0003047
- Condition identifier
- EFO_0003756
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003890
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004242
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004262
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004321
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007191
- Condition identifier
- EFO_0007453
- Condition identifier
- EFO_0007634
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009854
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009963
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009964
- Highest recorded phase
- 2
- Condition identifier
- EFO_0010282
- Condition identifier
- EFO_1001801
- Condition identifier
- EFO_1001892
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001908
- Condition identifier
- EFO_1001917
- Highest recorded phase
- 2
- Condition identifier
- HP_0000713
- Highest recorded phase
- 3
And 58 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- psychiatric toxicity
- Country
- United States
- Event
- agitation
- Reports
- 879
- Reporting signal score
- 844.181
- Event
- akathisia
- Reports
- 302
- Reporting signal score
- 455.153
- Event
- anxiety
- Reports
- 1,250
- Reporting signal score
- 756.619
- Event
- coma
- Reports
- 592
- Reporting signal score
- 584.984
- Event
- confusional state
- Reports
- 1,098
- Reporting signal score
- 678.179
- Event
- convulsion
- Reports
- 313
- Reporting signal score
- 227.611
- Event
- depression
- Reports
- 1,171
- Reporting signal score
- 664.938
- Event
- drug abuse
- Reports
- 902
- Reporting signal score
- 1,023.11
- Event
- drug interaction
- Reports
- 1,990
- Reporting signal score
- 1,623.37
- Event
- electrocardiogram qt prolonged
- Reports
- 1,441
- Reporting signal score
- 2,549.36
- Event
- hyponatraemia
- Reports
- 1,344
- Reporting signal score
- 1,703.7
- Event
- maternal drugs affecting foetus
- Reports
- 260
- Reporting signal score
- 401.913
- Event
- mydriasis
- Reports
- 328
- Reporting signal score
- 527.75
- Event
- poisoning deliberate
- Reports
- 132
- Reporting signal score
- 236.313
- Event
- restlessness
- Reports
- 437
- Reporting signal score
- 498.72
- Event
- serotonin syndrome
- Reports
- 1,292
- Reporting signal score
- 3,029.95
- Event
- small for dates baby
- Reports
- 225
- Reporting signal score
- 390.92
- Event
- somnolence
- Reports
- 1,161
- Reporting signal score
- 704.89
- Event
- sopor
- Reports
- 664
- Reporting signal score
- 1,089.77
- Event
- suicidal ideation
- Reports
- 963
- Reporting signal score
- 981.74
- Event
- suicide attempt
- Reports
- 1,410
- Reporting signal score
- 1,922.16
- Event
- temperature regulation disorder
- Reports
- 159
- Reporting signal score
- 466.833
- Event
- torsade de pointes
- Reports
- 286
- Reporting signal score
- 416.312
- Event
- toxicity to various agents
- Reports
- 1,012
- Reporting signal score
- 638.675
- Event
- tremor
- Reports
- 997
- Reporting signal score
- 571.229
- NCT00073411
- NCT00086307
- NCT00136318
- NCT00296933
- NCT00343070
- NCT00415142
- NCT00488670
- NCT00610506
- NCT00613470
- NCT00837564
- NCT00866593
- NCT00953108
- NCT01034995
- NCT01368432
- NCT01369095
- NCT02374567
- NCT02417064
- NCT02418585
- NCT02422186
- NCT02493868
- NCT02497287
- NCT02532660
- NCT03323697
- NCT03388164
- NCT03434041
And 120 more, listed on the interactive page.
- Dose
- 10 mg
- Route
- Oral
- How often
- Once daily
Conditions of use
- With or without food
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 0
- Polar surface area
- 36.26
- Calculated partition coefficient (ALogP)
- 3.81
- Calculated partition coefficient (XLogP)
- 3.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 24
- Molecular formula
- C20H21FN2O
- Monoisotopic mass
- 324.16379146
- Natural product
- No
- Recorded assays
- 564
- Active assays
- 34
- Confirmatory
- Other
- Screening
- Selective Serotonin Reuptake Inhibitors
Oral bioavailability
- Median
- 80
- Mean
- 80
- Minimum
- 80
- Maximum
- 80
- Unit
- %
- Assays
- 2
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (379)
- A Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram in Depression
- A Clinical Trial to Investigate the Pharmacokinetics and the Effect on ECG of Escitalopram in Elderly Volunteers
- A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
- A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment
- A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System
- A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
- A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression
- A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression
- A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram
- A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression
- A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol
- A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
- A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- A Study for Participants With Major Depression
- A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
- A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
- A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
- A Study of Patients With Major Depressive Disorder and Residual Apathy
- A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers
Approved for (2)
In development for (30)
- Alzheimer disease Phase 1
- Anxiety Phase 3
- Aphasia Phase 2
- Asthma Phase 2
- Autism spectrum disorder Phase 2
- Bipolar depression Phase 3
- Bipolar disorder Phase 3
- Borderline personality disorder Phase 2
- Burning mouth syndrome Phase 3
- Cancer Phase 3
- Carcinoma Phase 3
- Chronic kidney disease Phase 2
- Cocaine abuse Phase 2
- Cocaine dependence Phase 2
- Dementia Phase 3
- Drug dependence Phase 2
- Fibromyalgia Phase 2
- Generalized anxiety disorder Phase 3
- Hepatitis C virus infection Phase 1
- Hepatobiliary disorder Phase 2
Other linked conditions (5)
- Cannabis dependence
- Dissociative disorder
- Morbid obesity
- Postpartum depression
- Prurigo nodularis
Targets (1)
- SLC6A4 Serotonin transporter inhibitor